Matthias Englbrecht

Lehrstuhl für Innere Medizin III

COMPARATIVE CHANGE IN QUALITY OF LIFE MEASURES IN PRECLINICAL AND ESTABLISHED PSORIATIC ARTHRITIS PATIENTSUNDER SECUKINUMAB TREATMENT. DATA DERIVED FROM THE PROSPECTIVE OPEN LABEL PSARTROS STUDY (2019) Kampylafka E, Englbrecht M, Tascilar K, Lerchen V, Linz C, Kleyer A, Simon D, et al. Conference contribution New insights into the prevalence of depressive symptoms and depression in rheumatoid arthritis - Implications from the prospective multicenter VADERA II study (2019) Englbrecht M, Alten R, Aringer M, Baerwald CG, Burkharde H, Eby N, Flacke JP, et al. Journal article Interleukin 17 Blockade in Psoriasis Patients with Subclinical Joint Inflammation- Prospective Open Study to Influence the Course of the Disease by means of Secukinumab (2019) Kampylafka E, Oliveira I, Linz C, Lerchen V, Englbrecht M, Simon D, Rech J, et al. Conference contribution I would never take preventive medication! Perspectives and information needs of people who underwent predictive tests for rheumatoid arthritis (2019) Mosor E, Stoffer-Marx M, Steiner G, Raza K, Stack RJ, Simons G, Falahee M, et al. Journal article Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA (2019) Janssens R, Russo S, van Overbeeke E, Whichello C, Harding S, Kübler J, Juhaeri J, et al. Journal article Cost-effective tapering algorithm in patients with rheumatoid arthritis: Combination of multibiomarker disease activity score and autoantibody status (2019) Hagen M, Englbrecht M, Haschka J, Reiser M, Kleyer A, Hueber A, Manger B, et al. Journal article LOOSING DAS28-ESR, BUT STAYING IN BOOLEAN REMISSION-IS IT POSSIBLE? DATA FROM THE PROSPECTIVE, RANDOMISED RETRO TRIAL ON RHEUMATOID ARTHRITIS PATIENTS IN STABLE REMISSION (2018) Erhard J, Hagen M, Englbrecht M, Haschka J, Reiser M, Kleyer A, Hueber A, et al. Conference contribution BIOMECHANICAL PROPERTIES OF RADIAL BONE ARE DIFFERENT BETWEEN AUTO-ANTIBODY POSITIVE AND NEGATIVE RHEUMATOID ARTHRITIS (2018) Stemmler F, Simon D, Liphardt AM, Englbrecht M, Rech J, Hueber A, Engelke K, et al. Conference contribution Does an 18f-FDG-PET/CT in Patients with Giant Cell Arteritis in Clinical Remission Make Sense? (2018) Schoenau V, Roth JP, Englbrecht M, Rech J, Schett G Conference contribution DISEASE INTERCEPTION IN PSORIASIS PATIENTS WITH SUBCLINICAL JOINT INFLAMMATION BY INTERLEUKIN 17 INHIBITION WITH SECUKINUMAB - DATA FROM A PROSPECTIVE OPEN LABEL STUDY (2018) Kamoylafka E, Oliveira ID, Linz C, Lerchen V, Englbrecht M, Simon D, Sticherling M, et al. Conference contribution